AP1831A - Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia. - Google Patents
Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia.Info
- Publication number
- AP1831A AP1831A APAP/P/2001/002180A AP2001002180A AP1831A AP 1831 A AP1831 A AP 1831A AP 2001002180 A AP2001002180 A AP 2001002180A AP 1831 A AP1831 A AP 1831A
- Authority
- AP
- ARIPO
- Prior art keywords
- disorder
- disorders
- anxiety
- treatment
- psychotic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 208000019899 phobic disease Diseases 0.000 title abstract 2
- HRECXWVNLSVNGR-UHFFFAOYSA-N 6-chloro-5-[2-[4-(2-methylsulfonylbenzenecarboximidoyl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one Chemical compound ClC1=C(C=C2CC(NC2=C1)=O)CCN1CCN(CC1)C(C1=C(C=CC=C1)S(=O)(=O)C)=N HRECXWVNLSVNGR-UHFFFAOYSA-N 0.000 title 1
- 206010034912 Phobia Diseases 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 3
- 208000028017 Psychotic disease Diseases 0.000 abstract 3
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- NHUDBVVEHOSVCD-UHFFFAOYSA-N 6-chloro-5-[2-[4-(2-methylsulfanylbenzenecarboximidoyl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one Chemical compound CSC1=CC=CC=C1C(=N)N1CCN(CCC=2C(=CC=3NC(=O)CC=3C=2)Cl)CC1 NHUDBVVEHOSVCD-UHFFFAOYSA-N 0.000 abstract 1
- 208000008811 Agoraphobia Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000027691 Conduct disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 206010014557 Emotional poverty Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 208000027465 Psychotic Affective disease Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010041243 Social avoidant behaviour Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
This invention relates to pharmaceutical compositions containing S-methyl-dihydro-ziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric and ocular disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias (e.g., social phobia, agoraphobia etc.); psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorder associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioural disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with alzheimer's disease; drug-induced and neurodegeneration based dyskinesias; obsessive compulsive disorder; Tourette's syndrome; glaucoma; and ischemic retinopathy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20913600P | 2000-06-02 | 2000-06-02 | |
| US21217200P | 2000-06-16 | 2000-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP1831A true AP1831A (en) | 2008-02-26 |
Family
ID=26903852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2001/002180A AP1831A (en) | 2000-06-02 | 2001-05-31 | Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia. |
| AP2005003272A AP1747A (en) | 2000-06-02 | 2001-05-31 | Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2005003272A AP1747A (en) | 2000-06-02 | 2001-05-31 | Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal. |
Country Status (44)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7419493B2 (en) | 2002-12-13 | 2008-09-02 | Regents Of The University Of Minnesota | Scleral depressor |
| WO2005040160A2 (en) | 2003-10-24 | 2005-05-06 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| ES2250001B1 (en) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | PROCESS FOR THE PURIFICATION OF ZIPRASIDONA. |
| JP2012174228A (en) * | 2011-02-24 | 2012-09-10 | Kyocera Corp | Program protection device and communication apparatus |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059489A2 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ508303A (en) * | 1996-05-07 | 2001-07-27 | Pfizer | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist |
| TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| DK0985414T3 (en) * | 1998-05-26 | 2003-12-29 | Pfizer Prod Inc | Drug for the treatment of glaucoma and ischemic retinopathy |
-
2001
- 2001-05-28 DE DE60133596T patent/DE60133596D1/en not_active Expired - Lifetime
- 2001-05-28 YU YU90702A patent/YU90702A/en unknown
- 2001-05-28 PT PT04013380T patent/PT1468686E/en unknown
- 2001-05-28 AT AT06116051T patent/ATE391507T1/en not_active IP Right Cessation
- 2001-05-28 KR KR1020027016364A patent/KR20030007824A/en not_active Ceased
- 2001-05-28 SK SK1662-2002A patent/SK16622002A3/en not_active Application Discontinuation
- 2001-05-28 DE DE60124791T patent/DE60124791T2/en not_active Expired - Fee Related
- 2001-05-28 SI SI200130681T patent/SI1468686T1/en unknown
- 2001-05-28 OA OA1200200349A patent/OA12267A/en unknown
- 2001-05-28 EE EEP200200670A patent/EE200200670A/en unknown
- 2001-05-28 PT PT06116051T patent/PT1698338E/en unknown
- 2001-05-28 UA UA2002119557A patent/UA79425C2/en unknown
- 2001-05-28 GE GE4972A patent/GEP20053512B/en unknown
- 2001-05-28 EA EA200201168A patent/EA007068B1/en not_active IP Right Cessation
- 2001-05-28 HR HR20020953A patent/HRP20020953A2/en not_active Application Discontinuation
- 2001-05-28 EP EP06116051A patent/EP1698338B1/en not_active Expired - Lifetime
- 2001-05-28 CN CN01810620A patent/CN1431901A/en active Pending
- 2001-05-28 CA CA002410618A patent/CA2410618A1/en not_active Abandoned
- 2001-05-28 BR BR0111271-6A patent/BR0111271A/en not_active Application Discontinuation
- 2001-05-28 EP EP04013380A patent/EP1468686B1/en not_active Expired - Lifetime
- 2001-05-28 WO PCT/IB2001/000933 patent/WO2001091756A2/en not_active Ceased
- 2001-05-28 MX MXPA02011862A patent/MXPA02011862A/en active IP Right Grant
- 2001-05-28 AT AT01932011T patent/ATE343387T1/en not_active IP Right Cessation
- 2001-05-28 DK DK04013380T patent/DK1468686T3/en active
- 2001-05-28 PL PL01365576A patent/PL365576A1/en unknown
- 2001-05-28 NZ NZ551012A patent/NZ551012A/en unknown
- 2001-05-28 EP EP01932011A patent/EP1286672B1/en not_active Expired - Lifetime
- 2001-05-28 AU AU2001258690A patent/AU2001258690A1/en not_active Abandoned
- 2001-05-28 AT AT04013380T patent/ATE345818T1/en not_active IP Right Cessation
- 2001-05-28 DE DE60124093T patent/DE60124093D1/en not_active Expired - Lifetime
- 2001-05-28 ES ES04013380T patent/ES2277170T3/en not_active Expired - Lifetime
- 2001-05-28 JP JP2001587771A patent/JP2003534381A/en not_active Withdrawn
- 2001-05-28 HU HU0301747A patent/HUP0301747A2/en unknown
- 2001-05-28 IL IL15278201A patent/IL152782A0/en active IP Right Grant
- 2001-05-28 CZ CZ20023860A patent/CZ20023860A3/en unknown
- 2001-05-31 AP APAP/P/2001/002180A patent/AP1831A/en active
- 2001-05-31 HN HN2001000119A patent/HN2001000119A/en unknown
- 2001-05-31 PE PE2001000504A patent/PE20011329A1/en not_active Application Discontinuation
- 2001-05-31 DO DO2001000181A patent/DOP2001000181A/en unknown
- 2001-05-31 UY UY26742A patent/UY26742A1/en not_active Application Discontinuation
- 2001-05-31 AP AP2005003272A patent/AP1747A/en active
- 2001-06-01 SV SV2001000473A patent/SV2002000473A/en not_active Application Discontinuation
- 2001-06-01 AR ARP010102641A patent/AR028937A1/en unknown
- 2001-06-01 PA PA20018518301A patent/PA8518301A1/en unknown
- 2001-06-04 US US09/873,973 patent/US20060287336A1/en not_active Abandoned
-
2002
- 2002-11-11 IL IL152782A patent/IL152782A/en not_active IP Right Cessation
- 2002-11-12 BG BG107267A patent/BG107267A/en unknown
- 2002-11-14 IS IS6619A patent/IS6619A/en unknown
- 2002-11-28 ZA ZA200209665A patent/ZA200209665B/en unknown
- 2002-11-29 NO NO20025760A patent/NO325077B1/en unknown
- 2002-11-29 MA MA26927A patent/MA26908A1/en unknown
- 2002-11-29 EC EC2002004369A patent/ECSP024369A/en unknown
-
2007
- 2007-02-08 CY CY20071100161T patent/CY1105992T1/en unknown
- 2007-11-14 JP JP2007296039A patent/JP2008056700A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059489A2 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
Non-Patent Citations (1)
| Title |
|---|
| PRAKASH C ET AL: DRUG METABOLISM AND DISPOSITION, vol. 25, no. 7, July 1997, pages 863-872 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2256227A1 (en) | Method of treating psychiatric conditions | |
| CR10010A (en) | DERIVATIVES OF PYRIMIDINE, DERIVATIVES OF BENZODIAZEPINYL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| MA27596A1 (en) | BENZOCONDENSED HETEROARYLAMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR THEIR USE | |
| ATE416766T1 (en) | METHOD FOR PRODUCING 4-(2-DIPROPYLAMINOETHYL)-1,3-DIHYDRO-2H-INDOL-2-ONE-HYDROCHLORIDE | |
| BR9914293A (en) | Process for the purification of 1,3-propanediol | |
| DE69634414D1 (en) | USE OF SUBSTITUTED ISOCHINOLINSULFONYL COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF GLUCKOM AND OKULAR ISCHEMIA | |
| PT1586319E (en) | Thiadiazolidinones as gsk-3 inhibitors | |
| WO2000002542A3 (en) | Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug | |
| DK1689721T3 (en) | Aminopyrazole derivatives as GSK-3 inhibitors | |
| HUP0303281A2 (en) | Benzodiazepine derivatives as gaba a receptor modulators, process for their preparation and pharmaceutical compositions containing them | |
| AP1831A (en) | Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia. | |
| MX9307332A (en) | 3- (AMINOALKYLAMINE) -1,2-BENZSOXASOLES SUBSTITUTED AND RELATED COMPOUNDS. | |
| MA30693B1 (en) | PURINE DERIVATIVES AS A2A AGONISTS | |
| NO20060556L (en) | Quetiapinmetabolitt | |
| WO2009121155A3 (en) | Flavone containing compositions for treating mao associated disorders | |
| PT98427A (en) | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES WITH HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS | |
| WO2003106656A3 (en) | Single domain tdf-related compounds and analogs thereof | |
| DE69518159D1 (en) | MEDICINE FOR THE PREVENTION AND CURE OF TYPE I ALLERGIC DISEASES | |
| MY129575A (en) | Methods, kits and compositions for using pyrrole derivatives againts anxiety | |
| CA2376876A1 (en) | New isoindoloindolone derivatives, the process for preparing them and the pharmaceutical compounds that contain them | |
| IL166941A (en) | Piperidin-2,6-dione pamoate salts for the treatment of stress-related affective disorders | |
| CA2378628A1 (en) | New indenoindolone derivatives, the process for preparing them and the pharmaceutical compounds that contain them | |
| EP1364953A4 (en) | TRIAZOLOCHINAZOLINE AND PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES, MEDICAL COMPOSITIONS, MEDIUM WITH ADENOSINE A3 RECEPTORAFFINITY, MEDIUM WHICH REDUCES THE EYE PRESSURE, PREPARATIONS FOR PREVENTION AND PREVENTION PREVENTION | |
| Jaseja | Meditation and epilepsy: the ongoing debate | |
| WO2006013546A3 (en) | Process for the preparation of pure galantamine |